Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Rhea-AI Summary
Geron (Nasdaq: GERN) will release fourth quarter and full year 2025 financial results and business highlights before market open on Wednesday, February 25, 2026. The company will host a conference call and webcast at 8:00 a.m. Eastern Time.
Live and archived audio will be available from the Investors and Media section of the company's website at www.geron.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, GERN declined 0.62%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $1.07B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GERN is up 0.62% while key biotech peers show mixed moves, with several (e.g., AVXL, QURE, TSHA) down between roughly 2–9%, suggesting today’s action is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Financial guidance | Positive | +6.7% | 2026 guidance for RYTELO net product revenue and operating expenses. |
| Dec 18 | Inducement grant | Neutral | -0.8% | Inducement stock options for a new hire under Nasdaq Rule 5635(c)(4). |
| Dec 11 | Restructuring plan | Positive | +8.6% | Strategic restructuring with one‑third workforce reduction to lower 2026 expenses. |
| Dec 08 | Clinical data update | Positive | -3.0% | New RYTELO data at ASH 2025 in LR‑MDS and myelofibrosis. |
| Nov 05 | Earnings release | Positive | -5.2% | Q3 2025 revenue growth, narrowed net loss, and lower 2025 opex guidance. |
Recent news shows mixed reactions: guidance and restructuring updates saw gains, while strong clinical and earnings updates at times coincided with share declines.
Over the past few months, Geron has reported multiple milestones. On Nov 5, 2025, Q3 2025 results showed $47.2M in RYTELO net product revenue and narrowed net loss, but shares fell 5.22%. A strategic restructuring announced on Dec 11, 2025 targeting a one‑third workforce reduction led to an 8.59% gain. New RYTELO clinical data at ASH 2025 on Dec 8, 2025 saw a 3.05% decline. Financial guidance on Jan 12, 2026 drove a 6.72% rise. Today’s earnings-date notice fits into this cadence of regular investor updates.
Market Pulse Summary
This announcement sets the timing for Geron’s Q4 and full-year 2025 results on February 25, 2026, with a conference call at 8:00 a.m. Eastern Time. Ahead of that, recent history shows meaningful moves on guidance, restructuring, earnings, and clinical updates. Investors reviewing this event typically focus on upcoming disclosures about RYTELO revenue, operating expenses, and progress in key trials, alongside existing regulatory filings detailing the company’s financial position, debt structure, and recent corporate actions.
AI-generated analysis. Not financial advice.
FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with LR-MDS with transfusion-dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor R/R MF, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or LinkedIn.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
FAQ
When will Geron (GERN) release its Q4 and full year 2025 financial results?
What time is the Geron (GERN) conference call and webcast for the February 25, 2026 results?
How can investors access Geron (GERN) live and archived webcasts of the February 25, 2026 call?
Will Geron (GERN) include business highlights with its Q4 and full year 2025 financial release?
